G
Gina T. Mootrey
Researcher at Centers for Disease Control and Prevention
Publications - 33
Citations - 2220
Gina T. Mootrey is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Adverse Event Reporting System & Vaccination. The author has an hindex of 23, co-authored 33 publications receiving 2123 citations.
Papers
More filters
Journal Article
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Weigong Zhou,Vitali Pool,John K. Iskander,Roseanne English-Bullard,Robert Ball,Robert P. Wise,Penina Haber,Robert Pless,Gina T. Mootrey,Susan S. Ellenberg,M. Miles Braun,Robert T. Chen +11 more
TL;DR: This report summarizes the adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) from January 1, 1991, through December 31, 2001, and indicates that the most commonly reported adverse event was fever, which appeared in 25.8% of all reports.
Journal ArticleDOI
Postlicensure safety surveillance for varicella vaccine.
Robert P. Wise,Marcel E. Salive,M. Miles Braun,Gina T. Mootrey,Jane F. Seward,Lisa G. Rider,Philip R. Krause +6 more
TL;DR: Although the role of varicella vaccine remained unproven in most serious adverse event reports, there were a few positive rechallenge reports and consistency of many cases with syndromes recognized as complications of naturalvaricella.
Journal ArticleDOI
An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system
TL;DR: The Vaccine Adverse Event Reporting System (VAERS), the spontaneous reporting system for vaccine-associated adverse events in the United States, is evaluated as a public health surveillance system using evaluation guidelines from the Centers for Disease Control and Prevention.
Journal ArticleDOI
Adverse events associated with smallpox vaccination in the United States, January-October 2003.
Christine G. Casey,John K. Iskander,Martha H Roper,Eric E. Mast,Xiaojun Wen,Thomas J. Török,Louisa E. Chapman,David L. Swerdlow,Juliette Morgan,James D. Heffelfinger,Charles Vitek,Susan E. Reef,La Mar Hasbrouck,Inger K. Damon,Linda J. Neff,Claudia Vellozzi,Mary M. McCauley,Raymond A. Strikas,Gina T. Mootrey +18 more
TL;DR: Rigorous smallpox vaccine safety screening, educational programs, and older vaccinees may have contributed to low rates of preventable life-threatening adverse reactions.
Journal ArticleDOI
Advanced age a risk factor for illness temporally associated with yellow fever vaccination.
Michael Martin,Michael Martin,Leisa H. Weld,Theodore F. Tsai,Gina T. Mootrey,Robert T. Chen,Manette T. Niu,Martin S. Cetron,Jeff Altman,Vernon E. Ansdell,Elizabeth D. Barnett,Michele Barry,Bradley A. Connor,David O. Freedman,Alejandra Gurtman,Elaine Jong,Phyllis E. Kozarsky,Russell McMullen,Jan E. Patterson,Bradley R. Sack,Mary E. Wilson,Martin S. Wolfe +21 more
TL;DR: It is found that the rate of reported adverse events among elderly vaccinees was higher than among vaccinees 25 to 44 years of age, and two additional deaths among elderly YF vaccinees are found, suggesting enhanced surveillance is needed.